Pharmacological Treatment of Obesity: Current Standards and Future Perspectives

Author(s): J. A. Romijn, J. W.A. Smit, A. M. Pereira, E. P.M. Corssmit, H. Pijl

Journal Name: Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization)
Formerly Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents

Volume 6 , Issue 1 , 2006


The long-term effects on weight have only been studied for orlistat and sibutramine. The net effects of these drugs vary between 2-5% loss of weight after 1-2 years of treatment. However, the effects of orlistat and sibutramine on morbidity and mortality have not been studied extensively. In the past decade a huge amount of new knowledge has been gathered on the physiology of energy metabolism, satiety, gut-brain interactions, adipokines, adipogenesis, hypothalamic regulation etc. These studies have provided a multitude of new pharmacological targets for the treatment of obesity. Preclinical and clinical studies will have to prove the efficacy and safety of new drugs aimed at these new targets. The ultimate goal will be to reduce the increased morbidity and mortality, associated with obesity.

Keywords: Orlistat, sibutramine, obesity, hypothalamus, satiety, hormones

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Published on: 01 March, 2012
Page: [119 - 126]
Pages: 8
DOI: 10.2174/187152206775528842

Article Metrics

PDF: 14